These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 15721048)
21. Management of quality, capacity, and productivity at Merck. Nathan J; Venkataraman R Hosp Mater Manage Q; 1999 Feb; 20(3):64-9. PubMed ID: 10345635 [TBL] [Abstract][Full Text] [Related]
22. Trials and error. Jacobs T Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284 [No Abstract] [Full Text] [Related]
23. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297 [TBL] [Abstract][Full Text] [Related]
24. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry. Billette de Villemeur E; Versaevel B J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785 [TBL] [Abstract][Full Text] [Related]
25. Research and development productivity map: visualization of industry status. Shimura H; Masuda S; Kimura H J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433 [TBL] [Abstract][Full Text] [Related]
26. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Boyd RA; Lalonde RL Clin Pharmacol Ther; 2007 Jan; 81(1):24-6. PubMed ID: 17185993 [TBL] [Abstract][Full Text] [Related]
27. Innovative strategies for early clinical R&D. Butz RF; Morelli G IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261 [TBL] [Abstract][Full Text] [Related]
28. Measuring the efficiency of large pharmaceutical companies: an industry analysis. Gascón F; Lozano J; Ponte B; de la Fuente D Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446 [TBL] [Abstract][Full Text] [Related]
29. Organizing for innovation: towards successful translational research. West W; Nightingale P Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820 [TBL] [Abstract][Full Text] [Related]
30. Effective executive management in the pharmaceutical industry. Tran H; Kleiner BH J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973 [TBL] [Abstract][Full Text] [Related]
31. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. Glasser SP; Salas M; Delzell E J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697 [TBL] [Abstract][Full Text] [Related]
32. Is pharmaceutical R&D just a game of chance or can strategy make a difference? Schmid EF; Smith DA Drug Discov Today; 2004 Jan; 9(1):18-26. PubMed ID: 14761802 [TBL] [Abstract][Full Text] [Related]
33. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance. Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332 [TBL] [Abstract][Full Text] [Related]
34. Challenges in developing new antibacterial drugs. Williams KJ; Bax RP Curr Opin Investig Drugs; 2009 Feb; 10(2):157-63. PubMed ID: 19197793 [TBL] [Abstract][Full Text] [Related]
35. On the stage division mechanism in pharmaceuticals development processes. Dimitri N Drug Discov Today; 2008 Oct; 13(19-20):902-6. PubMed ID: 18678274 [TBL] [Abstract][Full Text] [Related]
36. The Indian and Chinese health biotechnology industries: potential champions of global health? Frew SE; Kettler HE; Singer PA Health Aff (Millwood); 2008; 27(4):1029-41. PubMed ID: 18607038 [TBL] [Abstract][Full Text] [Related]
37. Your alliances are too stable. Ernst D; Bamford J Harv Bus Rev; 2005 Jun; 83(6):133-41, 150. PubMed ID: 15938444 [TBL] [Abstract][Full Text] [Related]
38. Putting pharmacogenetics into practice. Hopkins MM; Ibarreta D; Gaisser S; Enzing CM; Ryan J; Martin PA; Lewis G; Detmar S; van den Akker-van Marle ME; Hedgecoe AM; Nightingale P; Dreiling M; Hartig KJ; Vullings W; Forde T Nat Biotechnol; 2006 Apr; 24(4):403-10. PubMed ID: 16601719 [TBL] [Abstract][Full Text] [Related]
39. The rise of micropharma. Barden CJ; Weaver DF Drug Discov Today; 2010 Feb; 15(3-4):84-7. PubMed ID: 19837185 [TBL] [Abstract][Full Text] [Related]
40. Experts predict bleak post-genomic era for drug R&D. Birmingham K Nat Med; 2001 Mar; 7(3):262. PubMed ID: 11231601 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]